In particular PC1/3 expressing cells, such as intestinal L-cells and pancreatic -cells, produce GLP-1, GLP-2 oxyntomodulin and glicentin (110, 112), while PC2 action on PG results in the production of glucagon and its active metabolite mini-glucagon (113, 114)
Based on the available clinical results, the FDA approved semaglutide for the following indications: In 2017, the FDA approved injectable semaglutide (brand name Ozempic) at a 1mg/weekly dose for treating type 2 diabetes (T2D) based on the results of the SUSTAIN program [12]
It also contributes to melanin production, which protects the eyes from light-induced damage
Oral formulations continue to be developed, which may reduce some barriers to use
When glutathione is administered orally, it is broken down into the three amino acids in the blood stream by peptidases in the blood